Primary and drug-induced disorders of water homeostasis in psychiatric patients: Principles of diagnosis and management

Harvard Review of Psychiatry

Volumn 6, Issue 4, 1998, Pages 190-200

  Siegel, Arthur J ^a,b   Baldessarini, Ross J ^a,b   Klepser, Marian B ^a,b   McDonald, Jane C ^a  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ARGIPRESSIN; CHLORPROPAMIDE; CLOZAPINE; DEMECLOCYCLINE; DESMOPRESSIN; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDOMETACIN; LITHIUM; PROSTAGLANDIN INHIBITOR; PSYCHOTROPIC AGENT; SODIUM CHLORIDE; SULFONYLUREA DERIVATIVE;

CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FLUID THERAPY; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INTRANASAL DRUG ADMINISTRATION; NEPHROGENIC DIABETES INSIPIDUS; ORAL DRUG ADMINISTRATION; POLYDIPSIA; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; WATER DEPRIVATION;

EID: 0031764592     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229809000329     Document Type: Review

References (53)

1. Riggs AT, Dysken MW, Kim SW, Opsahl JA. A review of disorders of water homeostasis in psychiatric patients. Psychosomatics 1991;32:133-48.
2. Illowsky BP, Kirch DG. Polydipsia and hyponatremia in psychotic patients. Am J Psychiatry 1988;145:675-83.
3. De Leon J, Verghese C, Tracy JI, Josiassen RC, Simpson GM. Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biol Psychiatry 1994; 35:408-19.
4. Patel JK. Polydipsia, hyponatremia, and water intoxication among psychiatric patients. Hosp Community Psychiatry 1994;45:1073-4.
5. Emsley RA, Van der Meer H, Aalbers C, Taljaard JJ. Inappropriate antidiuretic state in long-term psychiatric inpatients. S Afr Med J 1990;77:307-8.
6. Siegler EL, Tamres D, Berlin JA, Allen-Taylor L, Strom BL. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med 1995;155:953-7.
7. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Oilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 399-459.
8. Baldessarini RJ, Tondo L, Suppes T, Faedda GL, Toben M. Pharmacological treatment of bipolar disorder throughout the life-cycle. In: Shulman KI, Tohen M, Kutcher SP, eds. Mood disorders across the life span. New York: Wiley-Liss, 1996: 299-338.
9. Singer I, Oster JR, Fishman LM. The management of diabetes insipidus in adults. Arch Intern Med 1997;157:1293-301.
10. Moses AM, Streeten DHP. Disorders of the neurohypophysis. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1997:2003-10.
11. Goldman MB, Luchins DJ, Robertson GL. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med 1988;318:397-403.
12. Goldman MB, Robertson GL, Luchins DJ, Hedeker D. The influence of polydipsia on water excretion in hyponatremic, polydipsic, schizophrenic patients. J Clin Endocrinol Metab 1996;81:1465-70.
13. Vieweg WV, Hundley PL, Godleski LS, Tisdelle DA, Pruzinsky T, Yank GR. Diurnal weight gain as a predictor of serum sodium concentration in patients with psychosis, intermittent hyponatremia and polydipsia (PIP syndrome). Psychiatry Res 1988;26:305-12.
14. Vieweg WV. Treatment strategies in the polydipsia-hyponatremia syndrome. J Clin Psychiatry 1994;55:154-60.
15. Goldman MB, Nash M, Blake L, Petkovic MS. Do electrolyte-containing beverages improve water imbalance in hyponatremic schizophrenics? J Clin Psychiatry 1994;55:151-3.
16. Adams RD, Victor M, Ropper AH. The acquired metabolic disorders of the nervous system. In: Principles of neurology. 6th ed. New York: McGraw-Hill, 1997:1108-37.
17. Shevitz SA, Jameison RC, Petrie WM, Crook JE. Compulsive water drinking treated with high dose propranolol. J Nerv Ment Dis 1980;168:246-8.
18. Goldstein MB, Folsom T. The successful treatment of psychogenic polydipsia and water intoxication with propranolol: a case report. Minn Med 1991;74:29-32.
19. Greendyke RM, Bernhardt AJ, Tasbas HE, Lewandowski KS. Polydipsia in chronic psychiatric patients: therapeutic trials of clonidine and enalapril. Neuropsychopharmacology 1998; 18:272-81.
20. Lee HS, Kwon KY, Alphs LD, Meltzer HY. Effect of clozapine on psychogenic polydipsia in chronic schizophrenia [Letter]. J Clin Psychopharmacol 1991;11:222-3.
21. Munn NA. Resolution of polydipsia and hyponatremia in schizophrenic patients after clozapine treatment [Letter]. J Clin Psychiatry 1993;54:439.
22. Henderson DC, Goff DC. Clozapine for polydipsia and hyponatremia in chronic schizophrenics. Biol Psychiatry 1994;36: 768-70.
23. Leadbetter RA, Shutty MS Jr. Differential effects of neurolep-tic and clozapine on polydipsia and intermittent hyponatremia. J Clin Psychiatry 1994;55(suppl B):110-3.
24. Kostakoǧlu AE, Yazici KM, Erbaş T, Güvener N. Ketoacidosis as a side-effect of clozapine: a case report. Acta Psychiatr Scand 1996;93:217-8.
25. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-11.
26. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996; 57:514-8.
27. Kosten TR, Camp W. Inappropriate secretion of antidiuretic hormone in a patient receiving piperazine phenothiazines. Psychosomatics 1980;21:351, 354-5.
28. Peterson JC, Pollack RW, Mahoney JJ, Fuller TJ. Inappropriate antidiuretic hormone secondary to a monoamine oxidase inhibitor. JAMA 1978;239:1422-3.
29. Miller MG. Tricyclics as a possible cause of hyponatremia in psychiatric patients [Letter]. Am J Psychiatry 1989;146:807.
30. Pledger DR, Mathew H. Hyponatremia and clomipramine therapy. Br J Psychiatry 1989;154:263-4.
31. Khan A, McMurray JS, McCreery JM, Hunt HM. Carbamazepine and SIADH [Letter]. Am J Psychiatry 1989;146:1639.
32. Blacksten JV, Birt JA. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. Ann Pharmacother 1993;27:723-4.
33. Jackson C, Carson W, Markowitz J, Mintzer J. SIADH associated with fluoxetine and sertraline therapy [Letter]. Am J Psychiatry 1995;152:809-10.
34. Thornton SL, Resch DS. SIADH associated with sertraline therapy [Letter]. Am J Psychiatry 1995;152:809.
35. Ten Holt WL, Van Iperen CE, Schrijver G, Bartelink AK Severe hyponatremia during therapy with fluoxetine. Arch Intern Med 1996;156:681-2.
36. McEvoy GK. AHFS drug information - 97. Bethesda: American Society of Health-System Pharmacists, 1997.
37. Brewerton TD, Jackson CW. Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. J Clin Psychiatry 1994;55:249-51.
38. Wallin L, Alling C, Aurell M. Impairment of renal function in patients on long-term lithium treatment. Clin Nephrol 1982;18:23-8.
39. Decaux G, Prospert F, Namias B, Soupart A. Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia. Am J Med 1997;103: 376-82.
40. Taylor JW, Bell AJ. Lithium-induced parathyroid dysfunction: a case report and review of the literature. Ann Pharmacother 1993;27:1040-3.
41. Kallner G, Petterson U. Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1-30 years. Acta Psychiatr Scand 1995;91:48-51.
42. Allen HM, Jackson RL, Winchester MD, Deck IV, Allon M. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 1989;149:1123-6.
43. Neithercut WD, Spooner RJ, Hendry A, Dagg JH. Persistent nephrogenic diabetes insipidus, tubular proteinuria, amino-aciduria, and parathyroid hormone resistance following long-term lithium administration. Postgrad Med J 1990;66:479-82.
44. Bendz H, Aurell M, Balldin J, Mathé AA, Sjödin I. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994;9:1250-4.
45. Rafaelsen OJ, Bolwig TG, Ladefoged J, Bruc C. Kidney function and morphology in long-term treatment. In: Cooper TB, Gershon S, Kline N, Schou M, eds. Lithium: controversies and unresolved issues. Amsterdam: Excerpta Medica, 1979: 578-83.
46. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-45.
47. Blayney-Chandramouli J, Stokes JB. Use of ACE inhibitors in diabetic and nondiabetic patients with renal disease. Formulary 1998;33:318-40.
48. Gitlin MJ, Altshuler LL. Unanswered questions, unknown future for one of our oldest medications. Arch Gen Psychiatry 1997;54:21-3.
49. Tondo L, Baidessarini RJ, Hennen J, Floris G. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry 1998;155:638-45.
50. Lenox RH, Manji HK. Lithium. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:303-19.
51. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52:531-43.
52. Manji HK, Lenox RH, eds. Lithium: a unique cation in biology and medicine. Neuropsychopharmacology 1998; 19(3).
53. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12-21.